OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 187
Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 187
Showing 26-50 of 187 citing articles:
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Chien‐Tai Hong, Jia‐Hung Chen, Chaur‐Jong Hu
Journal of Biomedical Science (2024) Vol. 31, Iss. 1
Open Access | Times Cited: 11
Chien‐Tai Hong, Jia‐Hung Chen, Chaur‐Jong Hu
Journal of Biomedical Science (2024) Vol. 31, Iss. 1
Open Access | Times Cited: 11
The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: an anti-atherosclerotic action
Κλεοπάτρα Αλεξιάδου, Adam Hartley, Tricia M-M. Tan, et al.
Trends in Cardiovascular Medicine (2024)
Open Access | Times Cited: 10
Κλεοπάτρα Αλεξιάδου, Adam Hartley, Tricia M-M. Tan, et al.
Trends in Cardiovascular Medicine (2024)
Open Access | Times Cited: 10
Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss
Lalitha Sundararaman, Divakara Gouda, Anil Kumar, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 1978-1978
Open Access | Times Cited: 1
Lalitha Sundararaman, Divakara Gouda, Anil Kumar, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 1978-1978
Open Access | Times Cited: 1
Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study
Sara Volpe, Giuseppe Lisco, Davide Racaniello, et al.
Nutrients (2022) Vol. 14, Iss. 12, pp. 2414-2414
Open Access | Times Cited: 36
Sara Volpe, Giuseppe Lisco, Davide Racaniello, et al.
Nutrients (2022) Vol. 14, Iss. 12, pp. 2414-2414
Open Access | Times Cited: 36
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
Sara Battistella, Francesca D’Arcangelo, Marco Grasso, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S286-S301
Open Access | Times Cited: 34
Sara Battistella, Francesca D’Arcangelo, Marco Grasso, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S286-S301
Open Access | Times Cited: 34
DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
Michael Razavi, Yingying Wei, Xiaoquan Rao, et al.
Military Medical Research (2022) Vol. 9, Iss. 1
Open Access | Times Cited: 32
Michael Razavi, Yingying Wei, Xiaoquan Rao, et al.
Military Medical Research (2022) Vol. 9, Iss. 1
Open Access | Times Cited: 32
How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma
Konstantinos Arvanitakis, Theocharis Koufakis, Kalliopi Kotsa, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4651-4651
Open Access | Times Cited: 30
Konstantinos Arvanitakis, Theocharis Koufakis, Kalliopi Kotsa, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4651-4651
Open Access | Times Cited: 30
Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review
Panah Parab, Priti Chaudhary, Sonia Mukhtar, et al.
Cureus (2023)
Open Access | Times Cited: 20
Panah Parab, Priti Chaudhary, Sonia Mukhtar, et al.
Cureus (2023)
Open Access | Times Cited: 20
Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Huixing Liu, Di Fu, Daoquan Peng
Clinical Therapeutics (2023) Vol. 45, Iss. 1, pp. 17-30
Open Access | Times Cited: 18
Huixing Liu, Di Fu, Daoquan Peng
Clinical Therapeutics (2023) Vol. 45, Iss. 1, pp. 17-30
Open Access | Times Cited: 18
Diabetes mellitus treatment
Chin Meng Khoo
Elsevier eBooks (2023), pp. 417-427
Closed Access | Times Cited: 17
Chin Meng Khoo
Elsevier eBooks (2023), pp. 417-427
Closed Access | Times Cited: 17
Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives
Kosuke Sawami, Atsushi Tanaka, Koichi Node
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Kosuke Sawami, Atsushi Tanaka, Koichi Node
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Glucagon-Like Peptide Receptor Agonist Inhibits Angiotensin II-Induced Proliferation and Migration in Vascular Smooth Muscle Cells and Ameliorates Phosphate-Induced Vascular Smooth Muscle Cells Calcification
Jinmi Lee, Seok‐Woo Hong, Minjeong Kim, et al.
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 1, pp. 83-96
Open Access | Times Cited: 7
Jinmi Lee, Seok‐Woo Hong, Minjeong Kim, et al.
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 1, pp. 83-96
Open Access | Times Cited: 7
GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis
Mainak Banerjee, Rimesh Pal, Indira Maisnam, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 1, pp. 102943-102943
Closed Access | Times Cited: 7
Mainak Banerjee, Rimesh Pal, Indira Maisnam, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 1, pp. 102943-102943
Closed Access | Times Cited: 7
Resistant hypertension: Diagnosis, evaluation, and treatment practical approach
Roberto Parodi, Laura Brandani, César Romero, et al.
European Journal of Internal Medicine (2024) Vol. 123, pp. 23-28
Closed Access | Times Cited: 6
Roberto Parodi, Laura Brandani, César Romero, et al.
European Journal of Internal Medicine (2024) Vol. 123, pp. 23-28
Closed Access | Times Cited: 6
Heart failure with preserved ejection fraction epidemiology, pathophysiology, diagnosis and treatment strategies
Amr Abdin, Michael Böhm, Bahira Shahim, et al.
International Journal of Cardiology (2024) Vol. 412, pp. 132304-132304
Closed Access | Times Cited: 6
Amr Abdin, Michael Böhm, Bahira Shahim, et al.
International Journal of Cardiology (2024) Vol. 412, pp. 132304-132304
Closed Access | Times Cited: 6
Glucagon‐Like Peptide‐1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta‐Analysis of Randomized‐Controlled Trials
Alireza Hosseinpour, Aayushi Sood, Jahangir Kamalpour, et al.
Clinical Cardiology (2024) Vol. 47, Iss. 7
Open Access | Times Cited: 6
Alireza Hosseinpour, Aayushi Sood, Jahangir Kamalpour, et al.
Clinical Cardiology (2024) Vol. 47, Iss. 7
Open Access | Times Cited: 6
Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists
Hsuan-Wen Lai, Chun Yin See, Jui‐Yi Chen, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Hsuan-Wen Lai, Chun Yin See, Jui‐Yi Chen, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 6
GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 33
Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 33
Effects of glucose‐lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta‐analysis of randomized controlled trials with external adjudication of events
Edoardo Mannucci, Marco Gallo, Andrea Giaccari, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 2, pp. 444-453
Closed Access | Times Cited: 27
Edoardo Mannucci, Marco Gallo, Andrea Giaccari, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 2, pp. 444-453
Closed Access | Times Cited: 27
Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta‐analysis of randomized controlled trials
Andrea Iannone, Patrizia Natale, Suetonia C. Palmer, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 9, pp. 2535-2544
Open Access | Times Cited: 15
Andrea Iannone, Patrizia Natale, Suetonia C. Palmer, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 9, pp. 2535-2544
Open Access | Times Cited: 15
Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis
Yan Tang, Lin Zhang, Yuping Zeng, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 21
Yan Tang, Lin Zhang, Yuping Zeng, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 21
Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis
Jinjing Wei, Ruxin Wang, Haowen Ye, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 20
Jinjing Wei, Ruxin Wang, Haowen Ye, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 20
Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis
Jinjing Wei, Bin Yang, Ruxin Wang, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 20
Jinjing Wei, Bin Yang, Ruxin Wang, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 20
GLP-1 attenuates intestinal fat absorption and chylomicron production via vagal afferent nerves originating in the portal vein
Simon Hoffman, Danielle Alvares, Khosrow Adeli
Molecular Metabolism (2022) Vol. 65, pp. 101590-101590
Open Access | Times Cited: 19
Simon Hoffman, Danielle Alvares, Khosrow Adeli
Molecular Metabolism (2022) Vol. 65, pp. 101590-101590
Open Access | Times Cited: 19
Semaglutide-eye-catching results
Maja Cigrovski Berković, Felice Strollo
World Journal of Diabetes (2023) Vol. 14, Iss. 4, pp. 424-434
Open Access | Times Cited: 11
Maja Cigrovski Berković, Felice Strollo
World Journal of Diabetes (2023) Vol. 14, Iss. 4, pp. 424-434
Open Access | Times Cited: 11
